At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 5,897 enrolled
Drug / intervention
dabigatran dose 1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes
In Brief
A Phase 3 clinical trial evaluating dabigatran dose 1 and dabigatran dose 2 for Atrial Fibrillation. Completed, enrolled 5,897 participants across 567 sites in 35 countries.
Detailed Summary
The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesAustralia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Malaysia, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Korea, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedDec 2008
Primary CompletionDec 2012
TodayJul 2026
First PostedDec 15, 2008
Enrollment StartNov 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.5 years ago
Interventions
dabigatran dose 1drug
dabigatran high dose twice daily
dabigatran dose 2drug
dabigatran low dose twice daily